Factores clínicos asociados a la retinopatía del prematuro en neonatos tamizados con inteligencia artificial mediante VART Y RETCAM en una clínica de Barranquilla (2023–2024)
| datacite.rights | http://purl.org/coar/access_right/c_f1cf | |
| dc.contributor.advisor | Piñeros, Hildegard | |
| dc.contributor.advisor | Polo Gallardo, Raúl | |
| dc.contributor.author | Estupiñán Bucheli, María Isabel | |
| dc.contributor.author | Quintero Arciniegas, Laura | |
| dc.date.accessioned | 2025-07-03T19:30:19Z | |
| dc.date.available | 2025-07-03T19:30:19Z | |
| dc.date.issued | 2025 | |
| dc.description.abstract | Introducción: La retinopatía del prematuro ( ROP) es una de las principales causas de ceguera infantil prevenible, especialmente en países en desarrollo. En Barranquilla, donde la atención neonatal ha mejorado, persiste la necesidad de actualizar los datos sobre su incidencia, como también sobre las herramientas diagnósticas y terapéuticas más utilizadas. En este contexto, la inteligencia artificial (IA) se ha propuesto como una alternativa para mejorar el tamizaje oportuno y reducir la carga sobre el especialista. Objetivo: Determinar los factores clínicos asociados a la presencia y severidad de la retinopatía del prematuro en neonatos tamizados con inteligencia artificial mediante VART y RetCam en una clínica de Barranquilla durante el periodo 2023–2024. Materiales y métodos: Estudio observacional, transversal retrospectivo, con enfoque analítico, realizado entre enero de 2023 y diciembre de 2024. Se incluyeron 596 ojos de recién nacidos prematuros tamizados mediante el sistema RetCam y evaluados con inteligencia artificial (VART) en siete UCIN de Barranquilla. Se aplicaron análisis estadísticos descriptivos, pruebas inferenciales y regresión logística para identificar los factores asociados a la ROP. Resultados: La prevalencia de ROP fue del 19.5%. La edad gestacional promedio fue de 28.6 semanas y el peso al nacer de 1263.7 g. Se encontró una asociación significativa entre menor edad gestacional y bajo peso con la aparición de ROP (p<0.001). El 84.4% de los casos con ROP recibió tratamiento, siendo el láser la modalidad más utilizada (64.2 %), seguido de combinaciones con Anti-VEGF (26.5%). La IA empleada en el sistema VART demostró una sensibilidad del 80% para el tamizaje de ROP. | spa |
| dc.description.abstract | Introduction: Retinopathy of prematurity (ROP) is one of the leading causes of preventable childhood blindness, particularly in developing countries. In Barranquilla, where neonatal care has improved, there remains a need to update data on its incidence, as well as on the most commonly used diagnostic and therapeutic tools. In this context, artificial intelligence (AI) has been proposed as an alternative to improve timely screening and reduce the burden on specialists. Objective: To determine the clinical factors associated with the presence and severity of retinopathy of prematurity in neonates screened with artificial intelligence using VART and RetCam at a clinic in Barranquilla during the 2023–2024 period. Materials and Methods: Observational, cross-sectional, and retrospective study with an analytical approach, conducted between January 2023 and December 2024. A total of 596 eyes of premature newborns screened using the RetCam system and evaluated with artificial intelligence (VART) in seven NICUs in Barranquilla were included. Descriptive statistical analyses, inferential tests, and logistic regression were applied to identify factors associated with ROP. Results: The prevalence of ROP was 19.5%. The mean gestational age was 28.6 weeks, and the average birth weight was 1263.7 g. A significant association was found between lower gestational age and birth weight with the development of ROP (p < 0.001). Of the cases with ROP, 84.4% received treatment, with laser being the most commonly used modality (64.2%), followed by combinations with anti-VEGF (26.5%). AI used in the VART system demonstrated a sensitivity of 80% for ROP screening. | eng |
| dc.format.mimetype | ||
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/16795 | |
| dc.language.iso | spa | |
| dc.publisher | Ediciones Universidad Simón Bolívar | spa |
| dc.publisher | Facultad de Ciencias de la Salud | spa |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | eng |
| dc.rights.accessrights | info:eu-repo/semantics/embargoedAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject | Retinopatía del prematuro | spa |
| dc.subject | Prematuridad | spa |
| dc.subject | Inteligencia artificial | spa |
| dc.subject | Screening neonatal | spa |
| dc.subject | Factores de riesgo | spa |
| dc.subject | Anti-VEGF | spa |
| dc.subject | Fotocoagulación láser | spa |
| dc.subject.keywords | Retinopathy of prematurity | eng |
| dc.subject.keywords | Prematurity | eng |
| dc.subject.keywords | Artificial Intelligence | eng |
| dc.subject.keywords | Neonatal screening | eng |
| dc.subject.keywords | Risk factors | eng |
| dc.subject.keywords | Laser photocoagulation | eng |
| dc.title | Factores clínicos asociados a la retinopatía del prematuro en neonatos tamizados con inteligencia artificial mediante VART Y RETCAM en una clínica de Barranquilla (2023–2024) | spa |
| dc.type.driver | info:eu-repo/semantics/other | |
| dc.type.spa | Otros | |
| dcterms.references | Raghuveer TS, Zackula R. Strategies to Prevent Severe Retinopathy of Prematurity: A 2020 Update and Meta-analysis. NeoReviews. 2020;21(4): e249–63. doi: 10.1542/neo.21-4-e249.ProlactaBioScience+1Frontiers+1 | eng |
| dcterms.references | Tarnow-Mordi W, Kirby A. Current Recommendations and Practice of Oxygen Therapy in Preterm Infants. Clin Perinatol. 2019 Sep;46(3):621–36. doi: 10.1016/j.clp.2019.05.015. | eng |
| dcterms.references | Bujoreanu Bezman L, Tiutiuca C, Totolici G, Carneciu N, Bujoreanu FC, Ciortea DA, et al. Latest Trends in Retinopathy of Prematurity: Research on Risk Factors, Diagnostic Methods and Therapies. Int J Gen Med. 2023; 16:937–49. doi: 10.2147/IJGM.S405179. | eng |
| dcterms.references | Zhu T, Zhang L, Zhao F, Qu Y, Mu D. Association of maternal hypertensive disorders with retinopathy of prematurity: A systematic review and meta-analysis. PLoS One. 2017 Apr 7;12(4): e0175374. doi: 10.1371/journal.pone.0175374. | eng |
| dcterms.references | Tunay ZÖ, Özdemir Ö, Acar DE, Öztuna D, Uraş N. Maternal Diabetes as an Independent Risk Factor for Retinopathy of Prematurity in Infants With Birth Weight of 1500 g or More. Am J Ophthalmol. 2016 Aug; 168:201–6. doi: 10.1016/j.ajo.2016.05.006. | eng |
| dcterms.references | Organización Panamericana de la Salud. Síntesis de evidencia y recomendaciones: guía de práctica clínica para el manejo de la retinopatía de la prematuridad. Rev Panam Salud Pública. 2021 Dec 22; 45:1. | spa |
| dcterms.references | Pontificia Universidad Javeriana. Guía de atención integral del recién nacido prematuro [Internet]. 2012 [cited 2025 May]. Available from: https://scp.com.co/wp content/uploads/2014/08/3_GAI.p | spa |
| dcterms.references | Giraldo Restrepo MM, Hurtado Guzmán A, Donado Gómez JH, Molina Betancur MC. Epidemiología de la retinopatía del prematuro en Medellín, 2003–2008. Iatreia [Internet]. 2012 Feb 6 [cited 2025 Jan 2];24(3). Available from: https://revistas.udea.edu.co/index.php/iatreia/article/view/10545 | spa |
| dcterms.references | Abdala Caballero C, Acosta Reyes J, Izquierdo León MA. Caracterización de la retinopatía de la prematuridad entre el período de 2008 y 2014 en Barranquilla, Colombia. Rev Cienc Salud. 2015;3(48):213–22. | spa |
| dcterms.references | Esmeral D. Incidencia de la retinopatía de la prematuridad y factores neonatales asociados en el Área Metropolitana de Bucaramanga [Internet]. 2023 [cited 2025 May]. Available from: http://hdl.handle.net/20.500.12749/21288 | spa |
| dcterms.references | Brown AC, Nwanyanwu K. Retinopathy of prematurity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan– [updated 2023 Sep 4]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562319/ | eng |
| dcterms.references | Ministerio de Salud y Protección Social, Colciencias. Guía de práctica clínica del recién nacido prematuro. Guía No. 04. Bogotá, Colombia: Ministerio de Salud; 2013. | spa |
| dcterms.references | Consejo Privado de Competitividad. Algunos desafíos del sistema de salud en Colombia [Internet]. 2025 [cited 2025 May]. Available from: https://compite.com.co/blog_cpc/algunos-desafios-del-sistema-de-salud-en colombia | spa |
| dcterms.references | Gensure RH, Chiang MF, Campbell JP. Artificial intelligence for retinopathy of prematurity. Curr Opin Ophthalmol. 2020 Sep;31(5):312–7. doi:10.1097/ICU.0000000000000683 | eng |
| dcterms.references | Rallis D, Baltogianni M, Kapetaniou K, Giapros V. Current applications of artificial intelligence in the neonatal intensive care unit. BioMedInformatics. 2024 May 9;4(2):1225–48. doi:10.3390/biomedinformatics4020015 | eng |
| dcterms.references | Hong EH, Shin YU, Cho H. Retinopathy of prematurity: a review of epidemiology and current treatment strategies. Clin Exp Pediatr. 2022 Mar 15;65(3):115–26. doi:10.3345/cep.2021.00897 | eng |
| dcterms.references | Dammann O, Hartnett ME, Stahl A. Retinopathy of prematurity. Dev Med Child Neurol. 2023 May;65(5):625–31. doi:10.1111/dmcn.15255 | eng |
| dcterms.references | Rivera JC, Sapieha P, Joyal JS, Duhamel F, Shao Z, Sitaras N, et al. Understanding retinopathy of prematurity: update on pathogenesis. Neonatology. 2011;100(4):343– 53. doi:10.1159/000330628 | eng |
| dcterms.references | Organización Panamericana de la Salud. Guía de práctica clínica para el manejo de la retinopatía de la prematuridad. Washington, D.C.: OPS; 2018. | spa |
| dcterms.references | Kim SJ, Port AD, Swan R, Campbell JP, Chan RVP, Chiang MF. Retinopathy of prematurity: a review of risk factors and their clinical significance. Surv Ophthalmol. 2018 Sep;63(5):618–37. doi:10.1016/j.survophthal.2018.03.006 | eng |
| dcterms.references | Raghuveer TS, Zackula R. Strategies to prevent severe retinopathy of prematurity: a 2020 update and meta-analysis. NeoReviews. 2020 Apr;21(4):e249–63. doi:10.1542/neo.21-4-e249 | eng |
| dcterms.references | Tarnow-Mordi W, Kirby A. Current recommendations and practice of oxygen therapy in preterm infants. Clin Perinatol. 2019 Sep;46(3):621–36. doi:10.1016/j.clp.2019.05.003 | eng |
| dcterms.references | Bujoreanu Bezman L, Tiutiuca C, Totolici G, Carneciu N, Bujoreanu FC, Ciortea DA, et al. Latest trends in retinopathy of prematurity: research on risk factors, diagnostic methods and therapies. Int J Gen Med. 2023 Mar;16:937–49. doi:10.2147/IJGM.S390471 | eng |
| dcterms.references | Zhu T, Zhang L, Zhao F, Qu Y, Mu D. Association of maternal hypertensive disorders with retinopathy of prematurity: a systematic review and meta-analysis. PLoS One. 2017 Apr 7;12(4):e0175374. doi:10.1371/journal.pone.0175374 | eng |
| dcterms.references | Tunay ZÖ, Özdemir Ö, Acar DE, Öztuna D, Uraş N. Maternal diabetes as an independent risk factor for retinopathy of prematurity in infants with birth weight of 1500 g or more. Am J Ophthalmol. 2016 Aug;168:201–6. doi:10.1016/j.ajo.2016.05.027 | eng |
| dcterms.references | Wu WC, Ong FSC, Kuo JZC, Lai CC, Wang NC, Chen KJ, et al. Retinopathy of prematurity and maternal age. Retina. 2010 Feb;30(2):327–31. doi:10.1097/IAE.0b013e3181b5a0f8 | eng |
| dcterms.references | Schmidl D, Schmetterer L, Garhöfer G, Popa-Cherecheanu A. Gender differences in ocular blood flow. Curr Eye Res. 2015 Feb;40(2):201–12. doi:10.3109/02713683.2014.916020 | eng |
| dcterms.references | Dogra MR, Katoch D, Dogra M. An update on retinopathy of prematurity (ROP). Indian J Pediatr. 2017 Dec;84(12):930–6. doi:10.1007/s12098-017-2439-1 | eng |
| dcterms.references | Palmer EA. Results of U.S. randomized clinical trial of cryotherapy for ROP (CRYO ROP). Doc Ophthalmol. 1990 Mar;74(3):245–51. doi:10.100 | eng |
| dcterms.references | Chiang MF, Quinn GE, Fielder AR, Ostmo SR, Chan RVP, Berrocal A, et al. International classification of retinopathy of prematurity, third edition. Ophthalmology. 2021 Oct;128(10):e51–68. doi:10.1016/j.ophtha.2021.05.02 | eng |
| dcterms.references | Bancalari MA, Schade R. Retinopatía del prematuro: actualización en detección y tratamiento. Rev Chil Pediatr. 2020 Feb;91(1):122. | spa |
| dcterms.references | Reynolds JD. Evidence-based screening criteria for retinopathy of prematurity: natural history data from the CRYO-ROP and LIGHT-ROP studies. Arch Ophthalmol. 2002 Nov;120(11):1470. doi:10.1001/archopht.120.11.1470 | eng |
| dcterms.references | Fierson WM; American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists; Chiang MF, et al. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2018 Dec;142(6):e20183061. doi:10.1542/peds.2018-3061 | eng |
| dcterms.references | Ting DSW, Pasquale LR, Peng L, Campbell JP, Lee AY, Raman R, et al. Artificial intelligence and deep learning in ophthalmology. Br J Ophthalmol. 2019 Feb;103(2):167–75. doi:10.1136/bjophthalmol-2018-313173 | eng |
| dcterms.references | Brady CJ, D’Amico S, Campbell JP. Telemedicine for retinopathy of prematurity. Telemed J E Health. 2020 Apr;26(4):556–64. doi:10.1089/tmj.2019.0144 | eng |
| dcterms.references | Daich Varela M, Sen S, De Guimaraes TAC, Kabiri N, Pontikos N, Balaskas K, et al. Artificial intelligence in retinal disease: clinical application, challenges, and future directions. Graefes Arch Clin Exp Ophthalmol. 2023 Nov;261(11):3283–97. doi:10.1007/s00417-023-06141-7 | eng |
| dcterms.references | Early Treatment For Retinopathy of Prematurity Cooperative Group. Multicenter trial of early treatment for retinopathy of prematurity: study design. Control Clin Trials. 2004 Jun;25(3):311–25. doi:10.1016/j.cct.2004.04.003 | eng |
| dcterms.references | Sen P, Wu WC, Chandra P, Vinekar A, Manchegowda PT, Bhende P. Retinopathy of prematurity treatment: Asian perspectives. Eye (Lond). 2020 Apr;34(4):632–42. doi:10.1038/s41433-019-0714-8 | eng |
| dcterms.references | Khokhar S, Surve A, Verma S, Azad S, Chandra P, Dhull C, et al. Cataract in retinopathy of prematurity – a review. Indian J Ophthalmol. 2022 Feb;70(2):369–77. doi:10.4103/ijo.IJO_1465_21 | eng |
| dcterms.references | Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014 Nov;132(11):1327. doi:10.1001/jamaophthalmol.2014.1960 | eng |
| dcterms.references | Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011 Feb 17;364(7):603–15. doi:10.1056/NEJMoa1007374 | eng |
| dcterms.references | Wallace DK, Dean TW, Hartnett ME, Kong L, Smith LE, Hubbard GB, et al. A dosing study of bevacizumab for retinopathy of prematurity. Ophthalmology. 2018 Dec;125(12):1961–6. doi:10.1016/j.ophtha.2018.06.020 | eng |
| dcterms.references | Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019 Oct;394(10208):1551–9. doi:10.1016/S0140-6736(19)32460-9 | eng |
| dcterms.references | Marlow N, Stahl A, Lepore D, Fielder A, Reynolds JD, Zhu Q, et al. 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open-label, randomised controlled trial. Lancet Child Adolesc Health. 2021 Oct;5(10):698–707. doi:10.1016/S2352-4642(21)00192-4 | eng |
| dcterms.references | Stahl A, Sukgen EA, Wu WC, Lepore D, Nakanishi H, Mazela J, et al. Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: the FIREFLEYE randomized clinical trial. JAMA. 2022 Jul 26;328(4):348–57. doi:10.1001/jama.2022.10743 | eng |
| dcterms.references | Stahl A, Nakanishi H, Lepore D, Wu WC, Azuma N, Jacas C, et al. Intravitreal aflibercept vs laser therapy for retinopathy of prematurity: two-year efficacy and safety outcomes in the nonrandomized controlled trial FIREFLEYE next. JAMA Netw Open. 2024 Apr 30;7(4):e248383. doi:10.1001/jamanetworkopen.2024.8383 | eng |
| dcterms.references | Cusick M, Charles MK, Agrón E, Sangiovanni JP, Ferris FL, Charles S. Anatomical and visual results of vitreoretinal surgery for stage 5 retinopathy of prematurity. Retina. 2006 Sep;26(7):729–35. doi:10.1097/01.iae.0000222578.75856.a9 | eng |
| dcterms.references | Mintz-Hittner HA, O’Malley RE, Kretzer FL. Long-term form identification vision after early, closed, lensectomy-vitrectomy for stage 5 retinopathy of prematurity. Ophthalmology. 1997 Mar;104(3):454–9. doi:10.1016/S0161-6420(97)30103-9 | eng |
| dcterms.references | Bhavsar AR, editor. Operative techniques in vitreoretinal surgery. Philadelphia, PA: Elsevier; 2023. 320 p. | eng |
| dcterms.references | Rivera JC, Duchemin-Kermorvant E, Dorfman A, Zhou TE, Ospina LH, Chemtob S. Retinopathy of prematurity. In: Buonocore G, Bracci R, Weindling M, editors. Neonatology [Internet]. Cham: Springer International Publishing; 2018 [cited 2025 May 16]. p. 1–39. Available from: http://link.springer.com/10.1007/978-3-319-18159- 2_283-2 | eng |
| dcterms.references | Lakhanpal RR, Sun RL, Albini TA, Holz ER. Tasa de éxito anatómico tras vitrectomía con preservación del cristalino de 3 puertos en la retinopatía del prematuro en estadio 4A o 4B. Ophthalmology. 2005;112:1569–73. | spa |
| dcterms.references | Barnett JM, Hubbard GB. Complications of retinopathy of prematurity treatment. Curr Opin Ophthalmol. 2021 Sep;32(5):475–81. doi:10.1097/ICU.0000000000000768 | eng |
| dcterms.references | Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003 Dec 1;121(12):1684–94. doi:10.1001/archopht.121.12.1684 | eng |
| dcterms.references | Quinn GE, Dobson V, Repka MX, Reynolds J, Kivlin J, Davis B, et al. Development of myopia in infants with birth weights less than 1251 grams. Ophthalmology. 1992 Mar;99(3):329–40. doi:10.1016/S0161-6420(92)31501-9 | eng |
| dcterms.references | Rayess N, Rahimy E, Storey P, Shah CP, Wolfe JD, Chen E, et al. Postinjection endophthalmitis rates and characteristics following intravitreal bevacizumab, ranibizumab, and aflibercept. Am J Ophthalmol. 2016 May;165:88–93. doi:10.1016/j.ajo.2016.01.022 | eng |
| dcterms.references | Chandra P, Kumawat D, Tewari R, Azimeera S. Post-Ranibizumab injection endophthalmitis in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol. 2019;67(6):967–9. doi:10.4103/ijo.IJO_2163_18 | eng |
| dcterms.references | Thordsen JE, Harris L, Hubbard GB. Pediatric endophthalmitis: a 10-year consecutive series. Retina. 2008 Mar;28(3):S3–7. doi:10.1097/IAE.0b013e318160e98e | eng |
| dcterms.references | Paysse E. Acquired cataracts after diode laser photocoagulation for threshold retinopathy of prematurity. Ophthalmology. 2002 Sep;109(9):1662–5. doi:10.1016/S0161-6420(02)01114-2 | eng |
| dcterms.references | Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Arch Ophthalmol. 1988 Apr 1;106(4):471–9. doi:10.1001/archopht.1988.01060160075036 | eng |
| oaire.version | info:eu-repo/semantics/acceptedVersion | |
| sb.programa | Especialización en Oftalmología | spa |
| sb.sede | Sede Barranquilla | spa |
Archivos
Bloque de licencias
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- license.txt
- Tamaño:
- 2.93 KB
- Formato:
- Item-specific license agreed upon to submission
- Descripción: